Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.
Download
index.pdf
Date
2022-03-24
Author
Narci, Kubra
Kahraman, Deniz Cansen
Koyas, Altay
Ersahin, Tulin
Tuncbag, Nurcan
Atalay, Rengul Cetin
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
178
views
114
downloads
Cite This
Background: Targeted therapies for Primary liver cancer (HCC) is limited to the multi-kinase inhibitors, and not fully effective due to the resistance to these agents because of the heterogeneous molecular nature of HCC developed during chronic liver disease stages and cirrhosis. Although combinatorial therapy can increase the efficiency of targeted therapies through synergistic activities, isoform specific effects of the inhibitors are usually ignored. This study concentrated on PI3K/Akt/mTOR pathway and the differential combinatory bioactivities of isoform specific PI3K-alpha inhibitor (PIK-75) or PI3K-beta inhibitor (TGX-221) with Sorafenib dependent on PTEN context.
Subject Keywords
Liver Cancer
,
PI3K
,
Akt
,
mTOR pathway
,
Network analysis
,
Synergy
,
Resistance
,
SIGNALING PATHWAYS
,
PROLIFERATION
,
SORAFENIB
,
PROTEIN
,
OBESITY
,
GENES
URI
https://hdl.handle.net/11511/97295
Journal
BMC cancer
DOI
https://doi.org/10.1186/s12885-022-09357-y
Collections
Graduate School of Informatics, Article
Suggestions
OpenMETU
Core
Activation of survival pathways in nutrient restricted colorectal cancer cells
Oral, Göksu; Banerjee, Sreeparna; Department of Biology (2023-1-9)
Limited nutrient availability in the tumor microenvironment can cause metabolic rewiring of cancer cells, resulting in the activation of various stress response pathways such as autophagy for survival. Our study showed for the first time that incubation of LoVo cells with a nutrient restriction medium containing low glucose, glutamine, and serum for 48 h resulted in the concurrent activation of two antagonistic proteins: the AMP Kinase pathway (AMPK) which is phosphorylated in response to low energy and act...
Reversal of breast cancer resistance protein mediated multidrug resistance in MCF7 breast adenocarcinoma cell line
Urfalı, Çağrı; Gündüz, Ufuk; Department of Biology (2011)
Resistance to various chemotherapeutic agents is a major problem in success of cancer chemotherapy. One of the primary reasons of development of multidrug resistance (MDR) is the overexpression of ATP binding cassette (ABC) transporter proteins. Breast cancer resistance protein (BCRP) belongs to ABC transporter family and encoded by ABCG2 gene. BCRP is mainly expressed in MDR1 (P-glycoprotein) lacking breast cancer cells. Overexpression of BCRP leads to efflux of chemotherapeutic agents at higher rates, the...
Reversal of multidrug resistance in mcf-7 breast adenocarcinoma cell line by silencing interleukin 6 with RNA interference
Çakmak, Neşe; Gündüz, Ufuk; Department of Biology (2013)
Multidrug resistance (MDR) in cancer is characterized by development of resistance to several unrelated drugs upon long time administration of a certain type of chemotherapeutic agent. In doxorubicin resistant MCF-7 cell line, resistance is developed mainly by upregulation of MDR1 gene which encodes an ABC transporter protein known as P-glycoprotein. Interleukin 6 (IL-6) is a cytokine which acts as a growth factor for certain cell types including some cancer cells. IL-6 is found at high levels in cancer pat...
Synthesis of poly (dl-lactic-co-glycolic acid) coated magnetic nanoparticles for anti-cancer drug delivery
Tansık, Gülistan; Gündüz, Ufuk; Department of Biology (2012)
One of the main problems of current cancer chemotherapy is the lack of selectivity of anti-cancer drugs to tumor cells which leads to systemic toxicity and adverse side effects. In order to overcome these limitations, researches on controlled drug delivery systems have gained much attention. Nanoscale based drug delivery systems provide tumor targeting. Among many types of nanocarriers, superparamagnetic nanoparticles with their biocompatible polymer coatings can be targeted to an intented site by an extern...
Molecular investigation of therapeutical effects of Ɣ-tocotrienol conjugation therapy with doxorubicin on hepatocellular carcinoma cell line HePG2
Özyurt, İpek; Son, Çağdaş Devrim; Department of Biology (2017)
Hepatocellular carcinoma (HCC) is the fifth leading tumor of the liver tissue in terms of frequency of occurrence and third in terms of mortality. Even though, the most widely used chemotherapeutic agent doxorubicin in treatment of HCC had a great impact for development of therapeutic strategies preventing the progression of tumor formation and elucidating the physiological characteristics of tumor tissue. Moreover, use of doxorubicin minimizes the side effects of the drug in the individual and prevents the...
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
K. Narci, D. C. Kahraman, A. Koyas, T. Ersahin, N. Tuncbag, and R. C. Atalay, “Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.,”
BMC cancer
, vol. 22, no. 1, pp. 320–320, 2022, Accessed: 00, 2022. [Online]. Available: https://hdl.handle.net/11511/97295.